세계의 복잡성 요로감염증 치료 시장 보고서(2025년)

Complicated urinary tract infection (UTI) treatment refers to the management of urinary tract infections in individuals with underlying conditions that increase the risk of treatment failure. This treatment involves using targeted antibiotics and supportive therapies to address infections caused by resistant pathogens or other complications. It is particularly used for severe UTIs in patients with structural abnormalities, immunocompromised conditions, or catheter use, ensuring effective infection control and preventing further complications.

The main drug types for complicated urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combinations consist of antibiotics derived from penicillin, often combined with beta-lactamase inhibitors to enhance their effectiveness against resistant bacteria. These treatments are distributed through various channels, such as hospital pharmacies, gynecology and urology clinics, and drug stores. They are used for a range of conditions, including urethritis, cystitis, and pyelonephritis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The complicated urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides complicated urinary tract infection treatment market statistics, including the complicated urinary tract infection treatment industry global market size, regional shares, competitors with the complicated urinary tract infection treatment market share, detailed complicated urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. This complicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complicated urinary tract infection treatment market size has grown strongly in recent years. It will grow from $8.87 billion in 2024 to $9.44 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historical period can be attributed to the increasing prevalence of urinary tract infections, rising cases of antibiotic resistance, growing geriatric population, increased hospitalization rates, and rising awareness about UTIs.

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.03 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the growing prevalence of multidrug-resistant pathogens, increasing focus on precision medicine, rising healthcare expenditure, increased use of rapid diagnostic testing, government initiatives, and funding for research. Major trends in the forecast period advancements in diagnostic techniques, expanding healthcare access in emerging markets, development of novel antibiotics, technological advancements in diagnostic tools, and adoption of combination therapies.

The forecast of 6.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. urology care by inflating prices of carbapenem antibiotics and rapid urine culture systems developed in India and Italy, resulting in prolonged infections and higher antimicrobial stewardship program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive growth in the complicated urinary tract infection treatment market. CKD is a long-term condition marked by the gradual decline in kidney function over time. The rise in CKD cases is largely due to the growing rates of diabetes, hypertension, aging populations, and lifestyle factors such as obesity and smoking. Treatment for complicated urinary tract infections is crucial for CKD patients as it helps prevent severe infections such as pyelonephritis, which can worsen kidney damage, impair renal function, and accelerate the progression of CKD. This treatment reduces the risk of further complications and hospitalizations. For example, in December 2024, the Australian Institute of Health and Welfare reported that CKD was responsible for approximately 21,800 deaths in Australia in 2022. Moreover, in May 2024, Kidney Care UK stated that chronic kidney disease causes 40,000 to 45,000 premature deaths each year in the UK. Thus, the rising incidence of CKD is driving the growth of the complicated urinary tract infection treatment market.

Key companies in the complicated urinary tract infection treatment market are focusing on addressing antibiotic resistance through the development of novel antibiotics to improve treatment effectiveness and tackle emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infections involve using targeted antibiotics or antimicrobial agents to control infections, particularly in severe cases where the kidneys are affected. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which encourages the development of new anti-infective therapies. Clinical studies showed that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication), compared to 58.9% in those treated with piperacillin/tazobactam.

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to launch cefepime/enmetazobactam in India. This collaboration aims to leverage Cipla's distribution network to enhance the availability of cefepime/enmetazobactam, an antibiotic used to treat complicated urinary tract infections, including pyelonephritis. Cipla, a prominent India-based pharmaceutical company, focuses on providing advanced antibiotics and innovative healthcare solutions for treating complicated urinary tract infections.

Major players in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMerieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complicated Urinary Tract Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complicated urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complicated urinary tract infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The complicated urinary tract infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Penicillin And combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitro furans
• 2) By Distribution Channel: Hospital Pharmacies; Gynecology And Urology Clinics; Drug stores
• 3) By Application: Urethritis; Cystitis; Pyelonephritis
• Subsegments:
• 1) By Penicillin And Combinations: Aminopenicillins; Beta-Lactamase Inhibitor Combinations
• 2) By Quinolones: Fluoroquinolones; Non-Fluoroquinolones
• 3) By Cephalosporin: First-Generation Cephalosporins; Second-Generation Cephalosporins; Third-Generation Cephalosporins; Fourth-Generation Cephalosporins; Fifth-Generation Cephalosporins
• 4) By Azoles And Amphotericin B: Triazoles; Imidazoles; Polyene Antifungals
• 5) By Nitrofurans: Nitrofurantoin; Furazolidone
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; AstraZeneca PLC; Fresenius Kabi AG; GlaxoSmithKline plc; bioMerieux SA; Shionogi & Co. Ltd.; Cipla Limited; Santen Pharmaceutical Co. Ltd.; Orchid Pharma Limited; Melinta Therapeutics Inc.; Spero Therapeutics Inc.; Nabriva Therapeutics AG; Venatorx Pharmaceuticals Inc.; Recce Pharmaceuticals Ltd; MerLion Pharmaceuticals Pte. Ltd.; Entasis Therapeutics Holdings Inc.; Allecra Therapeutics GmbH; Allergan Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Complicated Urinary Tract Infection Treatment Market Characteristics

3. Complicated Urinary Tract Infection Treatment Market Trends And Strategies

4. Complicated Urinary Tract Infection Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Complicated Urinary Tract Infection Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Complicated Urinary Tract Infection Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Complicated Urinary Tract Infection Treatment Market Growth Rate Analysis
• 5.4. Global Complicated Urinary Tract Infection Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Complicated Urinary Tract Infection Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Complicated Urinary Tract Infection Treatment Total Addressable Market (TAM)

6. Complicated Urinary Tract Infection Treatment Market Segmentation

• 6.1. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillin And combinations
• Quinolones
• Cephalosporin
• Azoles And Amphotericin B
• Nitro furans
• 6.2. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Gynecology and Urology Clinics
• Drug stores
• Retail Pharmacies
• 6.3. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urethritis
• Cystitis
• Pyelonephritis
• 6.4. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Penicillin And Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aminopenicillins
• Beta-Lactamase Inhibitor Combinations
• 6.5. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Quinolones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluoroquinolones
• Non-Fluoroquinolones
• 6.6. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Cephalosporins
• Second-Generation Cephalosporins
• Third-Generation Cephalosporins
• Fourth-Generation Cephalosporins
• Fifth-Generation Cephalosporins
• 6.7. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Azoles And Amphotericin B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triazoles
• Imidazoles
• Polyene Antifungals
• 6.8. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Nitrofurans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrofurantoin
• Furazolidone

7. Complicated Urinary Tract Infection Treatment Market Regional And Country Analysis

• 7.1. Global Complicated Urinary Tract Infection Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Complicated Urinary Tract Infection Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Complicated Urinary Tract Infection Treatment Market

• 8.1. Asia-Pacific Complicated Urinary Tract Infection Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Complicated Urinary Tract Infection Treatment Market

• 9.1. China Complicated Urinary Tract Infection Treatment Market Overview
• 9.2. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Complicated Urinary Tract Infection Treatment Market

• 10.1. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Complicated Urinary Tract Infection Treatment Market

• 11.1. Japan Complicated Urinary Tract Infection Treatment Market Overview
• 11.2. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Complicated Urinary Tract Infection Treatment Market

• 12.1. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Complicated Urinary Tract Infection Treatment Market

• 13.1. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Complicated Urinary Tract Infection Treatment Market

• 14.1. South Korea Complicated Urinary Tract Infection Treatment Market Overview
• 14.2. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Complicated Urinary Tract Infection Treatment Market

• 15.1. Western Europe Complicated Urinary Tract Infection Treatment Market Overview
• 15.2. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Complicated Urinary Tract Infection Treatment Market

• 16.1. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Complicated Urinary Tract Infection Treatment Market

• 17.1. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Complicated Urinary Tract Infection Treatment Market

• 18.1. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Complicated Urinary Tract Infection Treatment Market

• 19.1. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Complicated Urinary Tract Infection Treatment Market

• 20.1. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Complicated Urinary Tract Infection Treatment Market

• 21.1. Eastern Europe Complicated Urinary Tract Infection Treatment Market Overview
• 21.2. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Complicated Urinary Tract Infection Treatment Market

• 22.1. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Complicated Urinary Tract Infection Treatment Market

• 23.1. North America Complicated Urinary Tract Infection Treatment Market Overview
• 23.2. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Complicated Urinary Tract Infection Treatment Market

• 24.1. USA Complicated Urinary Tract Infection Treatment Market Overview
• 24.2. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Complicated Urinary Tract Infection Treatment Market

• 25.1. Canada Complicated Urinary Tract Infection Treatment Market Overview
• 25.2. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Complicated Urinary Tract Infection Treatment Market

• 26.1. South America Complicated Urinary Tract Infection Treatment Market Overview
• 26.2. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Complicated Urinary Tract Infection Treatment Market

• 27.1. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Complicated Urinary Tract Infection Treatment Market

• 28.1. Middle East Complicated Urinary Tract Infection Treatment Market Overview
• 28.2. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Complicated Urinary Tract Infection Treatment Market

• 29.1. Africa Complicated Urinary Tract Infection Treatment Market Overview
• 29.2. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Complicated Urinary Tract Infection Treatment Market Competitive Landscape And Company Profiles

• 30.1. Complicated Urinary Tract Infection Treatment Market Competitive Landscape
• 30.2. Complicated Urinary Tract Infection Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Complicated Urinary Tract Infection Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. bioMerieux SA
• 31.3. Shionogi & Co. Ltd.
• 31.4. Cipla Limited
• 31.5. Santen Pharmaceutical Co. Ltd.
• 31.6. Orchid Pharma Limited
• 31.7. Melinta Therapeutics Inc.
• 31.8. Spero Therapeutics Inc.
• 31.9. Nabriva Therapeutics AG
• 31.10. Venatorx Pharmaceuticals Inc.
• 31.11. Recce Pharmaceuticals Ltd
• 31.12. MerLion Pharmaceuticals Pte. Ltd.
• 31.13. Entasis Therapeutics Holdings Inc.
• 31.14. Allecra Therapeutics GmbH
• 31.15. Allergan Inc.

32. Global Complicated Urinary Tract Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complicated Urinary Tract Infection Treatment Market

34. Recent Developments In The Complicated Urinary Tract Infection Treatment Market

35. Complicated Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Complicated Urinary Tract Infection Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Complicated Urinary Tract Infection Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Complicated Urinary Tract Infection Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer